<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(2)</volume><submitter>Karve S</submitter><funding>Eli Lilly and Company</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To assess real-world treatment patterns, health care utilization, costs, and survival among Medicare enrollees with locally advanced/unresectable or metastatic gastric cancer receiving standard first-line chemotherapy.&lt;h4>Materials and methods&lt;/h4>This was a retrospective analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database (2000~2009). The inclusion criteria were as follows: (1) first diagnosed with locally advanced/unresectable or metastatic gastric cancer between July 1, 2000 and December 31, 2007 (first diagnosis defined the index date); (2) ≥65 years of age at index; (3) continuously enrolled in Medicare Part A and B from 6 months before index through the end of follow-up, defined by death or the database end date (December 31, 2009), wh</pubmed_abstract><journal>Journal of gastric cancer</journal><pagination>87-104</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4496446</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.</pubmed_title><pmcid>PMC4496446</pmcid><pubmed_authors>Lorenzo M</pubmed_authors><pubmed_authors>Liepa AM</pubmed_authors><pubmed_authors>Kaye JA</pubmed_authors><pubmed_authors>Hess LM</pubmed_authors><pubmed_authors>Karve S</pubmed_authors><pubmed_authors>Calingaert B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.</name><description>&lt;h4>Purpose&lt;/h4>To assess real-world treatment patterns, health care utilization, costs, and survival among Medicare enrollees with locally advanced/unresectable or metastatic gastric cancer receiving standard first-line chemotherapy.&lt;h4>Materials and methods&lt;/h4>This was a retrospective analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database (2000~2009). The inclusion criteria were as follows: (1) first diagnosed with locally advanced/unresectable or metastatic gastric cancer between July 1, 2000 and December 31, 2007 (first diagnosis defined the index date); (2) ≥65 years of age at index; (3) continuously enrolled in Medicare Part A and B from 6 months before index through the end of follow-up, defined by death or the database end date (December 31, 2009), wh</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jun</publication><modification>2026-04-30T07:29:36.852Z</modification><creation>2019-03-27T01:54:50Z</creation></dates><accession>S-EPMC4496446</accession><cross_references><pubmed>26161282</pubmed><doi>10.5230/jgc.2015.15.2.87</doi></cross_references></HashMap>